Compare AstraZeneca plc (AZN) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs PepsiCo, Inc. — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while PepsiCo, Inc. trades at $135.8 (market cap $184.87B). The key difference: AstraZeneca plc is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| AZN | PEP | |
|---|---|---|
Market Cap | $253.13B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $170.44 |
52-Week Low | $137.44 | $133.81 |
Enterprise Value | $279.37B | $227.37B |
Dividend Yield | 1.92% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
PepsiCo (PEP) trades at $138.49, up 0.81% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly EPS beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and consistent earnings growth potential, though near-term technical weakness and pricing strategy adjustments present headwinds. The stock trades at reasonable valuation multiples (P/E 17.75) with upside to analyst targets, but investors should monitor North American performance recovery and consumer pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
